No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Uloric (febuxostat) is a medication used to treat hyperuricemia, a condition in which the body produces too much uric acid. It is used to reduce the risk of gout flares and to prevent the formation of kidney stones. Uloric is a xanthine oxidase inhibitor, which works by blocking the enzyme that produces uric acid. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperuricemia in adults with gout.
The Uloric market is a subset of the larger immune disorders drugs market. It is a growing market, driven by the increasing prevalence of gout and other immune disorders. The market is expected to benefit from the increasing awareness of gout and the availability of new treatments.
Companies in the Uloric market include Takeda Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Novartis. Show Less Read more
